Good evening :)
Stocks Collections

List of Shareholdings in the Ajay Piramal Portfolio (2026)

Ajay Piramal is one of India's most recognised industrialists and the chairman of the Piramal Group. He leads a diversified conglomerate with interests spanning pharmaceuticals, financial services, real estate, healthcare analytics, and glass packaging. His disclosed holdings amount to a 26.92% combined stake in Piramal Pharma Ltd., reflecting a high-conviction, founder-promoter approach to wealth concentration. His portfolio value has been supported by the Piramal Group's expansion across pharmaceuticals and financial services over several decades. This article explores Ajay Piramal's portfolio, profile, and investment approach.

Latest Ajay Piramal Stock Portfolio & Holdings (2026)

Ajay Piramal Portfolio Stock Screener

Ajay Piramal Portfolio Stock Screener: Analyse & Filter Indian Stocks on Tickertape

Created by

@tickertapetickertape

Showing 1 - 2 of 2 results

last updated at 6:30 AM IST 
NameStocks (2)↓↓Sub-SectorSub-Sector↓↓Market CapMarket Cap↓↓Close PriceClose Price↓↓PE RatioPE Ratio↓↓1D Return1D Return↓↓1M Return1M Return↓↓6M Return6M Return↓↓1Y Return1Y Return↓↓PB RatioPB Ratio↓↓Return on EquityReturn on Equity↓↓ROCEROCE↓↓Dividend YieldDiv Yield↓↓Debt to EquityDebt to Equity↓↓Volatility vs NiftyVolatility vs Nifty↓
1.Piramal Pharma LtdPPLPHARMAPharmaceuticalsPharmaceuticals23,082.3423,082.34174.24174.24-70.82-70.82-2.58-2.584.394.39-6.52-6.52-14.31-14.312.842.841.141.141.411.41--0.600.602.332.33
2.Piramal Finance LtdPIRAMALFINHome FinancingHome Financing524.08524.081,985.901,985.900.350.351.881.886.646.6426.2526.2550.1150.110.030.030.330.332.072.07--3.353.352.542.54
Edit Filters

Analyse Ajay Piramal Portfolio Stocks Further

Visit 'Ajay Piramal Portfolio' ScreenerScreener

Disclaimer: Please note that the above table is for informational purposes only, and is not recommendatory. Please do your own research or consult your financial advisor before investing. The data is derived from Tickertape Stock Screener and is subject to real-time updates.

Selection criteria: The table contains the publicly disclosed Ajay Piramal investment portfolio as on 21st May 2026. Stocks are sorted by market capitalisation, highest to lowest.

Ajay Piramal’s Bulk and Block Deals

Bulk and block deals improve market transparency and explain sharp changes in stock volumes. These disclosures help track where large investors deploy capital and which sectors attract or lose interest over time. Analysts often review such deals to understand portfolio shifts and changing market sentiment.


Here's how you can find the latest bulk and block deals by Ajay Piramal:

  1. Open Market Movers
  2. Under Party, type Ajay Piramal
  3. Select the relevant Category and Transaction Type

The results show Ajay Piramal's latest bulk and block deals. The platform also allows date filtering to review historical transactions and identify patterns over time.

Investor Profile – Ajay Piramal

Ajay Piramal is one of India's most recognised industrialists and the chairman of the Piramal Group. He was born on August 3, 1955, in Rajasthan, and took over his family's textile business at the age of 22. He transformed it into a diversified conglomerate spanning pharmaceuticals, financial services, real estate, healthcare analytics, and glass packaging. His most defining move came in 1988 when he acquired Nicholas Laboratories, laying the foundation for what would become Piramal Pharma. The group today operates across more than 100 countries.

  1. Name: Ajay Piramal
  2. Profession:Industrialist, Chairman of Piramal Group
  3. Education: B.Sc., Jai Hind College, Mumbai; Master of Management, Jamnalal Bajaj Institute of Management Studies, Mumbai
  4. Estimated net worth (₹): 6,309.9 cr. (varies by quarter)
  5. No. of portfolio companies: 2
  6. Primary focus: Pharmaceuticals, financial services, real estate, and healthcare

Ajay Piramal holds his publicly disclosed stake primarily through multiple entities -- personal holdings, the Ajay G. Piramal HUF, the Ajay G. Piramal Foundation, and the Sri Krishna Trust -- all concentrated in Piramal Pharma Ltd. His investment approach reflects a promoter-led, long-term commitment to the businesses he has built, rather than a diversified equity portfolio.

Top Stocks in Ajay Piramal Portfolio (2026)

Piramal Pharma Ltd

Piramal Pharma Ltd. is an Indian pharmaceutical company listed on NSE and BSE. It operates across complex hospital generics, consumer healthcare, and contract development and manufacturing. The company serves customers across India and international markets, with a presence in over 100 countries through its global manufacturing and research network.

Piramal Pharma Ltd

Piramal Finance Ltd. is a non-banking financial company regulated by the Reserve Bank of India. Formerly known as Dewan Housing Finance Corporation Ltd. (DHFL), it was acquired by the Piramal Group in 2021. It offers home loans, business loans, corporate financing, and deposit products, primarily serving retail and institutional borrowers across India.

Ajay Piramal Portfolio Composition

Here are the 2 active stocks publicly held by Ajay Piramal as of May 2026:

Stock Name Holding Value (In ₹ Cr) Shares Held Holding %
Piramal Pharma Ltd 6,309.9 357,843,540 26.92%
Piramal Finance Ltd - - Investor holds below 1%

How to Invest in Ajay Piramal Portfolio Stocks?

Here's how you can invest in Ajay Piramal's portfolio stocks using Tickertape -

  1. Create an account on the Tickertape or log in if you already have one.
  2. Open Ajay Piramal Portfolio Screener
  3. Filter stocks based on 200+ parameters. Tickertape provides comprehensive data on each stock, including financials, performance metrics, future projections, red flags, and more. You can review this data to assess each company's financial health and potential in depth.
  4. Once you've decided on a stock, you can place a buy order through your brokerage account linked to Tickertape.

You can stay updated with each of your favourite stocks' alerts and announcements with Tickertape Alerts. Further, you can analyse your overall portfolio and potential red flags in it by connecting it to Tickertape. Check out the detailed analysis of your portfolio now!

How to Invest in Ajay Piramal Portfolio Stocks?

Here's how you can invest in Ajay Piramal's portfolio stocks using Tickertape -

  1. Create an account on the Tickertape or log in if you already have one.
  2. Open Ajay Piramal Portfolio Screener
  3. Filter stocks based on 200+ parameters. Tickertape provides comprehensive data on each stock, including financials, performance metrics, future projections, red flags, and more. You can review this data to assess each company's financial health and potential in depth.
  4. Once you've decided on a stock, you can place a buy order through your brokerage account linked to Tickertape.

You can stay updated with each of your favourite stocks' alerts and announcements with Tickertape Alerts. Further, you can analyse your overall portfolio and potential red flags in it by connecting it to Tickertape. Check out the detailed analysis of your portfolio now!

Ajay Piramal's Investment Strategy

Buy Distressed, Sell at Peak Value

Piramal's approach centres on acquiring assets at low valuations, often from distressed sellers, and exiting at peak value. He bought a string of pharmaceutical companies -- including Nicholas Laboratories, Roche India, and Rhone Poulenc -- at around 1x revenues in the 1980s and sold the combined business to Abbott in 2010 at 9x sales and 30x EBITDA.

Acquisition Over Greenfield

Piramal has consistently favoured acquisitions and collaborations over building businesses from scratch. His approach prioritises picking up established businesses at low valuations, integrating them, and monetising their full potential over time.

Three-Principle Acquisition Framework

Piramal applies three principles to every acquisition: strategic fit evaluated honestly, discipline to avoid overpaying, and a relationship of trust with counterparties. He attributes multiple successful deals -- across Nicholas Laboratories, Roche, and Abbott -- to the trust built with counterparties rather than simply offering the highest price.

Capital Recycling into New Sectors

Following the Abbott sale in 2010, Piramal deployed the proceeds into Vodafone India and the Shriram Group, treating these as financial investments with defined exit timelines. He exited Vodafone in 2014 with a 52% return and later exited Shriram at over 100% gain.

Long-Term Value Over Short-Term Gains

Piramal's stated investment philosophy is to create long-term value for all stakeholders rather than pursue short-term financial returns. He draws a distinction between operational businesses, which he builds over decades, and financial investments, which he deploys with a clear return thesis and exit horizon.

Learnings From Ajay Piramal's Portfolio

Contrarian Timing Creates Outsized Value

Piramal bought multinational pharma assets when large MNCs were exiting India cheaply in the 1980s, and stayed away from infrastructure and real estate between 2007 and 2010 when those sectors attracted excessive capital. His willingness to take contrarian positions ahead of the market has defined his wealth creation track record.

Knowing When to Exit Matters as Much as Entry

Piramal is widely recognised not just for identifying good assets but for knowing when to exit. His exits from Vodafone India at a 52% return in two years and from the pharma formulations business at a record valuation are examples of this discipline in action.

Distressed Assets Can Be Rebuilt

The acquisition of DHFL, a debt-laden housing finance company, and its subsequent rebuilding under professional management into Piramal Finance demonstrates how distressed assets, acquired at the right price, can be turned into functional long-term businesses.

Trust as a Competitive Advantage

Piramal has consistently won acquisitions against higher bidders by building a reputation for reliability and ethical conduct. He credits trust, not price, as the primary reason why counterparties chose to transact with him across multiple deals over four decades.

Diversification Requires Patience and Capital Discipline

Piramal's transition from textiles to pharmaceuticals to financial services to real estate shows that successful diversification requires disciplined capital allocation and a willingness to wait for the right entry point, rather than chasing sectors at their peak.

Install the Tickertape app and enjoy a more hands-on investing experience
  • portfolio-iconReceive real-time market alerts for timely decisions
  • portfolio-iconMonitor your portfolio from the palm of your hands
  • portfolio-iconWatchlist stocks and mutual funds to stay updated
Download Now

Factors Affecting Stock Selection in Ajay Piramal Portfolio

Promoter Concentration in Core Business

Piramal's publicly disclosed equity is concentrated in Piramal Pharma Ltd., where his combined holdings across personal, HUF, foundation, and trust entities amount to a 26.92% stake valued at ₹6,309.9 cr. This reflects a promoter-led approach where financial interests remain aligned with the business he oversees.

Pharmaceutical Sector Fundamentals

Piramal Pharma operates across complex hospital generics, consumer healthcare, and contract development and manufacturing. The company's performance across domestic and international markets directly influences the portfolio's disclosed value.

Global Pharma Demand and CDMO Opportunity

Piramal Pharma's contract development and manufacturing business serves global pharmaceutical companies. Demand from regulated markets such as the US and Europe, along with pricing in those markets, affects revenue and profitability, which in turn influences the stock's valuation.

Promoter Holding Structure Across Entities

Piramal's stake in Piramal Pharma is held across multiple entities, personal, HUF, the Ajay G. Piramal Foundation, and the Sri Krishna Trust. Changes in any of these entities' holdings are reported to the exchanges and can affect public perception of promoter commitment to the business.

Conclusion

Ajay Piramal's publicly disclosed portfolio reflects the conviction of a promoter who has built, diversified, and scaled one of India's most recognised conglomerates over four decades. His concentrated holding in Piramal Pharma Ltd. demonstrates how long-term commitment to a structurally growing sector, backed by disciplined capital allocation and a proven track record of value creation, can drive meaningful wealth building over time.

However, investors should not copy or follow any investor's portfolio, no matter how appealing it appears. Every investor has different goals, risk tolerance, and time horizons. Investors should always do their own research. For independent analysis, investors can use the Tickertape Stock Screener, which offers 200+ filters to analyse stocks across fundamentals, valuations, and financial health. Investors can also track major stock activity and investor movements using Tickertape Market Movers.

Popular Stock Collections

Popular Mutual Fund Collections

Frequently Asked Questions About the Ajay Piramal Portfolio

  1. Who is Ajay Piramal?

    Ajay Gopikisan Piramal is an Indian billionaire businessman and the chairman of the Piramal Group, a conglomerate with interests in pharmaceuticals, financial services, real estate, healthcare analytics, and glass packaging. Born on August 3, 1955, in Rajasthan, he took over his family's textile business at the age of 22 and transformed it into a diversified global enterprise.

  2. What is Ajay Piramal's publicly disclosed portfolio value?

    As per corporate shareholding data filed for 31st March 2026, Ajay Piramal's publicly disclosed equity portfolio is valued at approximately ₹6,309.9 cr., with holdings in Piramal Pharma Ltd. This figure reflects only listed equity holdings and changes each quarter based on market price movements.

  3. What is the Piramal Group?

    The Piramal Group is a global business conglomerate with diverse interests in pharma, financial services, and real estate, with offices in over 30 countries and a brand presence in more than 100 markets. Its key subsidiaries include Piramal Pharma, Piramal Finance, Piramal Realty, and Piramal Foundation.

  4. What are the top holdings in the Ajay Piramal portfolio?

    As of 12th May 2026, Ajay Piramal’s only holding is in:
    1. Piramal Pharma Ltd
    2. Piramal Pharma Ltd

  5. What was Ajay Piramal's biggest investment deal?

    Piramal's most defining deal was the 2010 sale of Piramal Healthcare's branded generics business to Abbott Laboratories at 9x sales and 30x EBITDA, the highest-ever multiple paid globally for a branded generics business at the time.

  6. How does Ajay Piramal approach acquisitions?

    Piramal applies three principles to every acquisition: strategic fit evaluated honestly, price discipline to avoid overpaying, and a relationship of trust with counterparties. He has attributed several successful deals to being chosen over higher bidders because of the trust built with sellers.

  7. What is Piramal Pharma and why does Ajay Piramal hold it?

    Piramal Pharma operates a diversified pharmaceutical business spanning contract development and manufacturing through Piramal Pharma Solutions, complex hospital generics through Piramal Critical Care, and over-the-counter consumer healthcare products in India. Ajay Piramal founded and built this business over decades, and his promoter stake reflects long-term ownership of the core group entity.

Disclaimer: This article is for informational purposes only. The content of the article, including securities/investment products mentioned, if any, should not in any manner be construed as investment advice, recommendation, offer, or solicitation to buy/hold/sell any securities/investment products. The securities quoted, if any, are for illustration only and are not recommendatory. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered financial advisor before investing.